» Articles » PMID: 30279962

Role of Textural Heterogeneity Parameters in Patient Selection for 177Lu-PSMA Therapy Via Response Prediction

Overview
Journal Oncotarget
Specialty Oncology
Date 2018 Oct 4
PMID 30279962
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Prostate cancer is most common tumor in men causing significant patient mortality and morbidity. In newer diagnostic/therapeutic agents PSMA linked ones are specifically important. Analysis of textural heterogeneity parameters is associated with determination of innately aggressive and therapy resistant cell lines thus emphasizing their importance in therapy planning. The objective of current study was to assess predictive ability of tumor textural heterogeneity parameters from baseline Ga-PSMA PET prior to Lu-PSMA therapy.

Results: Entropy showed a negative correlation (r = -0.327, = 0.006, AUC = 0.695) and homogeneity showed a positive correlation (r = 0.315, = 0.008, AUC = 0.683) with change in pre and post therapy PSA levels.

Conclusions: Study showed potential for response prediction through baseline PET scan using textural features. It suggested that increase in heterogeneity of PSMA expression seems to be associated with an increased response to PSMA radionuclide therapy.

Materials And Methods: Retrospective analysis of 70 patients was performed. All patients had metastatic prostate cancer and were planned to undergo Lu-PSMA therapy. Pre-therapeutic Ga- PSMA PET scans were used for analysis. 3D volumes (VOIs) of 3 lesions each in bones and lymph nodes were manually delineated in static PET images. Five PET based textural heterogeneity parameters (COV, entropy, homogeneity, contrast, size variation) were determined. Results obtained were then compared with clinical parameters including pre and post therapy PSA, alkaline phosphate, bone specific alkaline phosphate levels and ECOG criteria. Spearman correlation was used to determine statistical dependence among variables. ROC analysis was performed to estimate the optimal cutoff value and AUC.

Citing Articles

Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients.

Kleiburg F, de Geus-Oei L, Spijkerman R, Noortman W, van Velden F, Manohar S Eur Radiol. 2025; .

PMID: 39843627 DOI: 10.1007/s00330-025-11360-3.


Prostate-Specific Membrane Antigen-Positron Emission Tomography-Guided Radiomics and Machine Learning in Prostate Carcinoma.

Maes J, Gesquiere S, Maes A, Sathekge M, Van de Wiele C Cancers (Basel). 2024; 16(19).

PMID: 39409989 PMC: 11475246. DOI: 10.3390/cancers16193369.


Multicentric Ga-PSMA PET radiomics for treatment response assessment of Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Gutsche R, Gulmus G, Mottaghy F, Gartner F, Essler M, von Mallek D Front Nucl Med. 2024; 3:1234853.

PMID: 39355016 PMC: 11440964. DOI: 10.3389/fnume.2023.1234853.


Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?.

Lancia A, Ingrosso G, Detti B, Festa E, Bonzano E, Linguanti F Front Oncol. 2024; 14:1455428.

PMID: 39314633 PMC: 11417306. DOI: 10.3389/fonc.2024.1455428.


Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.

Yazdani E, Geramifar P, Karamzade-Ziarati N, Sadeghi M, Amini P, Rahmim A Diagnostics (Basel). 2024; 14(2).

PMID: 38248059 PMC: 10814892. DOI: 10.3390/diagnostics14020181.


References
1.
Zaidi H, Abdoli M, Fuentes C, El Naqa I . Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2012; 39(5):881-91. PMC: 3326239. DOI: 10.1007/s00259-011-2053-0. View

2.
Mathieu C, Ferrer L, Carlier T, Colombie M, Rusu D, Kraeber-Bodere F . Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with (18)F-Choline PET/CT in Prostate Cancer. Front Med (Lausanne). 2015; 2:67. PMC: 4563255. DOI: 10.3389/fmed.2015.00067. View

3.
Divrik R, Turkeri L, Sahin A, Akdogan B, Ates F, Cal C . Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer. Urol Int. 2011; 88(1):25-33. DOI: 10.1159/000334539. View

4.
Cheng N, Fang Y, Chang J, Huang C, Tsan D, Ng S . Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. J Nucl Med. 2013; 54(10):1703-9. DOI: 10.2967/jnumed.112.119289. View

5.
Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A . Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. J Nucl Med. 2016; 57(9):1334-8. DOI: 10.2967/jnumed.116.173757. View